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Abstract
Pediatric patients with solid tumors have unacceptably low cure rates, and
immunotherapy, such as oncolytic virotherapy, provides great promise for treatment. However,
there is a lack of knowledge regarding the immunosuppressive microenvironment of solid
tumors, and how this microenvironment affects the efficacy of virotherapy and other cancer
immunotherapies. Tumor-Associated Macrophages, TAMs, specifically, M-2 like macrophages,
and Myeloid Derived Suppressor Cells, MDSCs, are two key targets for improving the efficacy
of immunotherapies as both play roles in immunosuppression. As such, it is suspected that a
combined treatment that both reduces myelolytic cells in the microenvironment while
stimulating a pro-inflammatory response will increase cytotoxic immune infiltration in the tumor
microenvironment. We have previously demonstrated that trabectedin, an FDA-approved
chemotherapy drug, in combination with oncolytic HSV, oHSV, has shown to stimulate tumor
regression in two Ewing sarcoma Patient Derived Xenograft, PDX, models10. Our proposed
mechanism suggests that trabectedin targets tumor-associated M2-like macrophages, and both
depletes their levels while also polarizing remaining macrophages to an M1-like macrophage,
which can perform phagocytosis against the tumor. While two Ewing sarcoma PDX models have
demonstrated tumor regression in response to this combined myelolytic-virotherapy, it is
unknown if these effects are generalizable to other non-Ewing sarcoma pediatric models or
syngeneic models. This thesis explores the use of a combination treatment of the oncolytic virus,
HSV1716, with the chemotherapy agent, trabectedin, in murine osteosarcoma. Specifically, this
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Current treatments for pediatric cancer solid tumors include surgery, radiation, and
chemotherapy. However, suboptimal cure rates, especially in cases of malignant or recurrent
disease, require that new treatment options be made available. Additionally, for children who
survive adolescence and into adulthood, the long-term side-effects of current treatments may
limit quality of life. Immunotherapy, thought to produce fewer long-term side effects than current
treatments, provides a promising field for the development of new treatment options for pediatric
patients1. Immunotherapy enhances the immune system’s ability to detect and eliminate cancer.
Immunotherapy agents include antibody therapy, adoptive therapy, checkpoint inhibitors, and
oncolytic viruses1.
Solid tumors are situated within a complex environment of infiltrating stromal and
immune cells as well as extracellular components, such as cytokines and growth factors, that
promote an immunosuppressive environment2,3. The tumor microenvironment varies for each
tumor model, however, myeloid-derived suppressor cells, MDSCs, and tumor-associated
macrophages, TAMs, are prominent infiltrating cells2. TAMs are plastic cells which allow them
to change their phenotypic expression in response to cell signaling. M1-like macrophages are
activated by interferon gamma (IFNγ) and display anti-tumor effects by releasing
pro-inflammatory cytokines to recruit other immune cells to the microenvironment and by direct
phagocytosis of the tumor2,4. However, most TAMs within the tumor microenvironment are
polarized to the M2- like phenotype by interleukin (IL)-4, IL-13, IL-10, and colony-stimulating
factor (CSF) 12. The M2-like macrophage is associated with a protumorigenic response by
secreting factors that promote proliferation, immunosuppression, and angiogenesis such as
vascular endothelial growth factor A (VEGF-A) and transforming growth factor β (TGFβ)2,4.
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TAMs are abundant in pediatric solid tumors, and high TAM infiltrate in the tumor
microenvironment is associated with poor prognosis2,5. As such, there is a need for therapies that
both target the tumor and the tumor microenvironment.
Oncolytic viruses selectively infect and kill cancer cells through either direct lysis or by
promoting an antitumor immune response1,6. Currently, the only FDA-approved oncolytic virus is
talimogene laherparepvec (T-VEC), an attenuated herpes simplex type-1 (HSV-1) for the
treatment of advanced melanoma in adult patients. T-VEC is engineered with the deletions of the
neurovirulence gene RL1 which encodes ICP34.5, and the deletion of ICP47. Additionally, the
granulocyte–macrophage colony-stimulating factor (GM-CSF) promoter is inserted into T-VEC7.
A similar oncolytic virus, HSV1716, has been proven to be safe in pediatric patients following a
phase I clinical trial for patients with relapsed non-CNS solid tumors8. HSV1716, an HSV-1
strain 17 derivative, contains the deletion of RL1 gene encoding ICP34.58. While the clinical trial
did demonstrate the safety of a single intratumoral injection and that the virotherapy was
well-tolerated by the patients, no objective responses were seen8. Conclusions from this study
suggest that oncolytic viruses as a single-agent treatment may not be effective for pediatric
cancer, and combination treatments with other immunotherapeutics or chemotherapies should be
investigated.
This thesis explores the use of a combination treatment of the oncolytic virus, HSV1716
with the chemotherapy agent, trabectedin. Originally isolated from a marine source, trabectedin
is a DNA binder that activates caspase-8-dependent apoptosis in myelomonocytic cells9.
Additionally, it has been shown to deplete MDSCs and TAMs, which is a key component of
trabectedin’s anti-tumor efficacy9. In a 2018 study, the Cripe Lab combined trabectedin with the
oHSV, rRp450. This study was conducted in two Ewing sarcoma Patient Derived Xenograft,
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PDX, models, and the combination of trabectedin and oHSV led to tumor regression in 78% of
the treatment group10. However, it is unclear if this combination myelolytic-virotherapy therapy
will produce similar results in non-Ewing pediatric solid tumors, and studies to test this
treatment’s generalizability are ongoing.
Osteosarcoma is the most common form of pediatric bone cancer, and this disease
typically occurs in the long bones such as the femur or tibia. Current treatments for localized
disease have a 5- year survival rate of 78%11. Once the disease has metastasized, it often travels
to the lungs. The survival rate for metastatic disease is only between 10-30%12. This poor
prognosis following metastasis requires new treatment options to be made available. However,
difficulties with treating osteosarcomas include that they are poorly immunogenic tumors due to
a lack of tumor neo-antigens for targeting and low levels of CD8 infiltrate in the
microenvironment. As such, they are characterized as cold tumors, a feature that is common
among pediatric cancers11. One study demonstrated that human osteosarcoma xenograft mouse
models responded to two intratumoral injections of the oHSV, rRp45013. Given that
osteosarcomas have demonstrated previous sensitivity to oHSV, osteosarcoma became one of the
targets for determining if the combination therapy of oHSV and trabectedin is generalizable to
other models outside of Ewing sarcoma.
In order to determine the generalizability of the combination therapy, murine tumor
models of osteosarcoma were studied in immunocompetent mice. Unlike the studies seen in the
PDX models, the treatment in murine, immunocompetent models produced extreme toxicity.
This toxicity included rapid weight loss and respiratory distress. While the combination
treatment remains promising, the focus of my research has shifted from assessing the
generalizability of the treatment to mitigating the combination treatment’s toxicity while
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maintaining its efficacy. As such, this thesis details the studies performed to control the toxicity
of the combination therapy of the oHSV, HSV1716, and the chemotherapy agent, trabectedin.
Preliminary Data
Survival Study of F420 implanted Immunocompetent Mice Treated with HSV1716 and
Trabectedin
The first study of the combination therapy in immunocompetent mice was with the
murine osteosarcoma model, F420. Figure 1. shows a schematic of the treatment regimen. To
summarize, the mice were injected subcutaneously with 5.0x106 F420 cells. Once the tumors
reached approximately 150 to 200 mm3, the treatment began. The mice were divided into four
study groups: PBS alone injected intratumorally on day 0, 2, and 4, HSV1716 injected
intratumorally on day 0, 2, and 4, Trabectedin alone administered intravenously via the tail vein
on day 0 and 7, and the combination treatment of trabectedin administered intravenously on day
0 and 7 with HSV1716 being injected intratumorally on day 0, 2, and 4. HSV1716 was
administered at a concentration of 1.0x108 pfu, and trabectedin was administered at a dose of
0.15mg/kg. The tumors were then measured twice a week with calipers. Once the mice reached
the endpoint criteria which included either excess tumor burden (tumor size greater than
2000mm3), tail necrosis, or a 20% reduction in body weight, the mice were euthanized. To note,
trabectedin is vesicant that can cause tail necrosis if it comes in contact with the skin. As such,
tail blistering is common if the drug leaks during the tail vein injection.
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Figure 2. shows the tumor progression data from the survival study. This figure
demonstrates that the combination of trabectedin with HSV1716 is able to control tumor growth
better than either HSV1716 or trabectedin alone at early time points in the survival study. This
suggests that the combination treatment does demonstrate efficacy. However, of the nine mice in
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the combination group, six of the mice were either found dead or had to be euthanized due to
toxicity. For the mice that had to be euthanized, increased respiratory rate and loss of body
weight were symptomatic of the toxicity. Comparatively, only two of the nine mice treated with
trabectedin alone succumbed to toxicity, and zero of the ten mice treated with HSV1716 alone
had to be euthanized due to toxicity. Figure 3 shows the body weights of each mouse during the
study. Table 1 provides a summary of the cause for study termination for each cohort.
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Reduction of Trabectedin Dose Levels to Reduce Toxicity
In an effort to address the toxicity, researchers in the Cripe lab performed a dose
de-escalation study with the trabectedin being reduced from 0.15 mg/kg to 0.075 mg/kg, 0.0375
mg/kg, 0.0188 mg/kg, 0.0094 mg/kg, and 0.0047 mg/kg. The mice of this study were divided
into five groups for each dose of trabectedin, and then administered the combination HSV1716
and trabectedin treatment according to the treatment schedule outlined in Figure 1. The
concentration of HSV1716 remained the same as the initial study at 1.0x108 pfu. Figure 4 shows
the tumor volume progression data for each mice cohort. By day 14, none of the cohorts
demonstrated the ability to either reduce tumor volume or prevent further tumor enlargement.
However, no mice in any of the groups succumbed to toxicity. As such, at all doses of trabectedin
at and below 0.075 mg/kg, it can be concluded that both the efficacy and the toxicity of the
combination treatment was eliminated.
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Reduction in Number of Trabectedin Doses to Reduce Toxicity
The next experiment performed by Cripe lab researchers was to use the initial dose of
trabectedin (0.15 mg/kg) with the number of doses being administered reduced from two
administered on day 0 and 7, to just one dose administered on day 0. The dosing regimen for
HSV1716 (1.0x108 pfu) remained the same as the one outlined in Figure 1. In this survival study,
the trabectedin alone group, like the combination treatment group, was only administered one
dose of trabectedin on day 0. Figure 5 depicts the tumor volume progression data for each of the
four cohorts (PBS alone, HSV1716 alone, trabectedin alone, and combination HSV1716 with
trabectedin). In figure 5, the tumor volume progression indicates that the combination treatment
is able to control tumor volume progression slightly better than the trabectedin alone group at
early time points. However, Figure 6 demonstrates that the percent survival of the trabectedin
alone group and the combination group remained similar. As such, it can be concluded that the
elimination of the second dose of trabectedin limited the efficacy of the combination treatment.
Additionally, of the thirteen mice in the trabectedin alone group, two had to be euthanized due to
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toxicity. Then, in the combination treatment group seven of the fourteen mice had to be
euthanized due to toxicity. Therefore, elimination of the second dose did not significantly
improve the toxicity of the combination treatment. Table 2 provides a summary of the cause for
study termination for each cohort.
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Evaluation of the Effect of T Cells on Tumor Response
The final preliminary experiment was to evaluate the effect of T cells on the myleloytic
virotherapy by injecting F420 cells on the flank of athymic nude mice and following the
treatment schedule outlined in figure 1. Figure 7 shows the average tumor volume progression
data for each of the four cohorts, and HSV1716 alone, trabectedin alone, and the combination
treatment of HSV1716 and trabectedin exhibit similar trends. As such, it can be concluded that
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the tumor response is limited in the athymic nude strain. However, weight loss due to toxicity is
also absent in the athymic nude mice. Figure 8 compares the body weights of mice receiving the
same treatment regimen outlined in Figure 1 in C57BL/6 mice and athymic (nu/nu) mice. This
figure demonstrates that toxicity due to weight loss correlates with either T cell presence or
mouse strain.
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Conclusions from Preliminary Data
From the experiments and results outlined above, the Cripe lab researchers came to
several conclusions. First, reducing the amount of trabectedin delivered either by reducing the
dose amount or by eliminating the second dose did not lead to adequate tumor response.
Furthermore, the toxicity was only controlled when the dose amount was reduced. In this case,
toxicity was controlled, yet efficacy was lost. However, the second dose elimination study
exhibited a loss of efficacy while maintaining toxicity. As such, it seems critical that both doses
of trabectedin be administered for maintaining the efficacy of the treatment, and that the
therapeutic window of trabectedin is greater than 0.075 mg/kg. Then from the athymic nude
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study it can be concluded that treatment efficacy and toxicity seem to correlate with either T cells
or mouse strain.
Introduction to Thesis Experiments
Despite the challenges with managing the toxicity and efficacy of the combination
treatment, we continued to pursue the treatment due to the promising results seen in Ewing
sarcoma10. However, instead of focusing on the generalizability of the combination treatment, we
instead focused on finding a way to mitigate the toxicity of the combination treatment in the
immunocompetent model while maintaining efficacious tumor responses. To do this, we first
sought to determine the mechanism of the toxicity. After consulting with Dr. Timothy Cripe MD,
PhD, and PI of the lab, two mechanisms were proposed for the toxicity including tumor lysis
syndrome and cytokine release syndrome.
When tumor cells lyse, they release potassium, phosphorus, and nucleic acids into the
bloodstream which can lead to electrolyte and metabolic disturbances14. Diagnosis of laboratory
tumor lysis syndrome includes the presence of two or more of the following metabolic
abnormalities: hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.
Additionally, the onset of these metabolic disturbances must occur three to seven days following
treatment initiation. Clinically, these disturbances are associated with toxic side effects such as
death due to multiorgan failure14.
Cytokine release syndrome is a systemic inflammatory response that can be caused by
both infection and drug treatment. Like tumor lysis syndrome, it can lead to multiorgan failure
and death. Notably, cytokine release syndrome is among the most frequent adverse events that
can occur following t-cell engaging immunotherapy15. The most commonly elevated cytokines in
people experiencing cytokine release syndrome include IL-6, IL-10, and IFNγ. Additionally, in
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murine models of cytokine release syndrome, IL-6 signaling pathways have been implicated in
directing the pathophysiology of the syndrome. As such, blocking IL-6 signaling pathways via
monoclonal antibody therapy is a treatment for cytokine release syndrome that can be applied in
severe cases.
The first set of experiments for the thesis included determining whether tumor lysis
syndrome or cytokine release syndrome was occurring in mice treated with the combination
treatment. Then, based upon those study results, we then completed survival studies with
additional therapeutics. Our final experiment in the study involved reducing the dose of
trabectedin again to determine the therapeutic window in which the treatment toxicity was
minimized while maintaining effective tumor responses.
Thesis Experiments
Determining if Tumor Lysis Syndrome or Cytokine Release Syndrome is occurring in Mice
Treated with the Combination Therapy of HSV1716 and Trabectedin
To determine if the mice bearing F420 tumors treated with the combination treatment
were experiencing tumor lysis syndrome, we sent blood serum to the hospital laboratory at
Nationwide Children’s Hospital to complete a metabolic panel. Prior to sending the serum, we
administered one dose of trabectedin at 0.15 mg/kg, and the mice either received HSV1716
according to the dosing regimen in Figure 1, or they only received the single trabectedin dose.
Then, on day 7 after the single trabectedin dose was administered, the mice were euthanized and
their blood was collected via retro-orbital bleeding. The blood samples were centrifuged to
separate the serum, and then the serum was sent for analysis. The metabolic panel measured
albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, blood
urine nitrogen (BUN), calcium, creatinine, lactate dehydrogenase (LDH), sodium, potassium,
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chloride, carbon dioxide, total protein, and uric acid. Figure 9 shows the results from the
metabolic panel. If tumor lysis syndrome was occurring, we anticipated seeing elevated
potassium and phosphorus with low calcium. None of these were far outside of the normal range
described in the literature for C57BL/6 albino mice. This suggests that tumor lysis syndrome is
not the mechanism for causing the toxicity, However, both ALT and AST enzymes were elevated
suggesting evidence of hepatotoxicity.
We then completed a mouse-specific cytokine array panel using serum from the same
four mice that we also used for the metabolic panel. As such, the mice either received one dose
of trabectedin and HSV1716 or just one dose of trabectedin alone. Additionally, the cytokine
array panel shows only four samples as that is the maximum number that can be tested with one
kit. We chose to use two combination treatment samples, one trabectedin alone sample, and one
control sample. Figure 10 shows the results from the cytokine array panel. The only cytokine that
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was present in the combination treatment samples, but absent from both the control and
trabectedin alone samples was granulocyte colony-stimulating factor (G-CSF).
G-CSF is a pro-inflammatory cytokine that induces the mobilization of neutrophils from
bone marrow to the periphery. The role of G-CSF in solid tumors and in the tumor
microenvironment is limited. However, one group out of the University of New Mexico studied
Anti G-CSF treatment in colorectal cancers17. Interestingly, they found that anti G-CSF treatment
led to a reduction of IL-10 and an increase in IFNγ. As noted in the introduction of the paper,
M2-like macrophages are protumorigenic and are polarized to the M2 phenotype by IL-10
whereas M1-like macrophages are polarized by IFNγ. As such, anti G-CSF treatment could
influence macrophage polarization from protumorigenic to anti- tumorigenic. Additionally, if
G-CSF was playing a role in the toxicity of the combination treatment, reduction of G-CSF by
treating the mice with anti G-CSF antibodies would lead to a reduction in the toxicity.
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Evaluating Anti G-CSF Treatment on Reducing the Toxicity of the Combination Treatment of
HSV1716 with Trabectedin
To evaluate the effect of anti G-CSF antibody treatment in mice injected with F420
tumors, we completed a pilot study. Ten mice were injected subcutaneously with 5.0x106 F420
cells. Once the tumors reached 150 mm2 - 200 mm2 treatment began. As with previous studies,
trabectedin was administered on day 0 and day 7 at a dose of 0.15 mg/kg via the tail vein and
HSV1716 was administered on day 0, day 2, and day 4 intratumorally at a dose of 1.0x108 pfu.
Anti G-CSF antibody injected intraperitoneally at a dose of 25µg dissolved in 100µL of PBS.
Anti G-CSF was administered on day 0, day 2, and day 4. Figure 11 shows the tumor volume
progression for each mouse in the study. Of note, one mouse was found dead on day 7 of the
experiment, and one mouse had to be euthanized on day 10 due to low body weight. Therefore,
the anti G-CSF treatment was not successful at preventing toxicity.
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Figure 12 shows the anti G-CSF cohort in comparison to cohorts of mice in previous
studies receiving trabectedin alone, HSV1716 alone, and the combination treatment of HSV1716
and trabectedin. The anti G-CSF cohort was not able to control or reduce tumor growth as well
as the combination trabectedin and HSV1716 group. As such, the addition of anti G-CSF therapy
neither improved toxicity or maintained the efficacy of the combination treatment.
Combining Dexamethasone with the Combination of Trabectedin and HSV1716 to Control
Toxicity
Following the negative results from the anti G-CSF study, we turned to the literature to
reexamine if any groups had success controlling the toxicity of trabectedin alone. We found one
group that utilized dexamethasone as a pretreatment prior to the administration of trabectedin to
ameliorate the drug-induced hepatotoxicity (High-Dose Dexamethasone). Dexamethasone is a
steroid commonly used to treat inflammation. The study authors concluded that a single high-
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dose pretreatment with dexamethasone was sufficient to control toxicity without limiting the
efficacy of the treatment18. However, this study was predominantly completed in the Wistar rat.
Based upon the promising results in the literature, we completed a survival study with a
dexamethasone pretreatment to examine its ability to reduce the toxicity in the combination
treatment in the F420 model. Mice were injected subcutaneously with 5.0x106 F420 cells. Once
the tumors reached 150 mm2 - 200 mm2 treatment began. Figure 13 provides a schematic of the
treatment regimen. To summarize, 48 hours prior to the first treatment with trabectedin and
HSV1716, all mice were treated with 40 mg/kg of dexamethasone via an intraperitoneal
injection. Then, 24 hours prior to treatment all mice received a second pretreatment of the
dexamethasone (40 mg/kg delivered via an intraperitoneal injection). On day 0, the mice were
divided into their respective cohorts: PBS, HSV1716 (1.0x108 pfu), trabectedin (0.15 mg/kg), and
combination HSV1716 and trabectedin. HSV1716 was administered intratumorally on day 0,
day 2, and day 4. Trabectedin was administered on day 0 and day 7. The mice were then
measured with calipers twice a week to measure tumor growth.
23
Of the fourteen mice in the combination group, four mice were either euthanized or found
dead due to the toxicity of the treatment. As such, the toxicity of the treatment was not
significantly reduced with the pretreatment with the dexamethasone. Figure 14 shows the percent
survival of the four cohorts, and the combination treatment was not more efficacious. Ultimately,
we concluded that dexamethasone did not markedly reduce the toxicity and it limited the
combination treatments efficacy rendering it an ineffective treatment addition.
Exploring the Therapeutic Window of Trabectedin in a Second Dose De-escalation Study
With negative results from both anti G-CSF treatment and dexamethasone pretreatment,
we returned to evaluating the therapeutic window of trabectedin. The therapeutic window refers
to the dose concentration at which the drug is effective but has limited toxicity. Going too far
below the therapeutic window will result in a loss of efficacy whereas going above the
therapeutic window will lead to extreme toxicity. Previous studies have reported that the
therapeutic window of trabectedin is narrow, so we decided to only drop the dose of trabectedin
from 0.15 mg/kg to 0.125 mg/kg and 0.10 mg/kg16. In contrast, our first dose de-escalation study
reduced the dose of trabectedin in half and then continued to decrease the dose.
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In accordance with our previous animal studies, we began by injecting mice
subcutaneously with 5.0x106 F420 cells. Once the tumors reached 150 mm2 - 200 mm2 treatment
began. The mice were divided into two cohorts: the combination of HSV1716 (1.0x108 pfu) with
trabectedin (0.125 mg/kg) and the combination of HSV1716 (1.0x108 pfu) with trabectedin (0.10
mg/kg). The dosing regimen remained the same with HSV1716 being administered
intratumorally on day 0, day 2, and day 4. Trabectedin was delivered via the tail vein on day 0
and day 7. This study is currently ongoing at the time of submitting this thesis, so completed data
is not available to determine if either of the trabectedin dose groups produced similar efficacy to
the standard 0.15 mg/kg treatment we had been using for our studies. However, of the 26 mice in
the study, 5 mice had to be euthanized due to weight loss associated with toxicity. Therefore,
further investigation into managing the toxicity of the combination treatment is warranted.
Conclusions and Future Directions
After completing several experiments to mitigate the toxicity of the combination
treatment, we have remained unsuccessful in both controlling the toxicity while simultaneously
maintaining efficacy. From our metabolic panel, we were able to eliminate both tumor lysis
syndrome and cytokine release syndrome as causes of the treatment toxicity. However, our
cytokine array panel indicated that G-CSF may be playing a role in the toxicity seen in the
combination treatment, anti G-CSF antibody therapy did not eliminate the toxicity. Additionally,
this treatment limited the efficacy of the combination treatment. Then, we used dexamethasone
in an attempt to control the toxicity. Similar to the ant G-CSF study, pretreatment with
dexamethasone did not lead to a significant reduction in toxicity, and it limited the efficacy of the
combination treatment. Finally, we returned to examining the therapeutic window of the
trabectedin by lowering the dose from 0.15 mg/kg to 0.125 mg/kg and 0.10 mg/kg. This study is
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currently ongoing, but early analysis indicates that reducing the trabectedin dose still leads to
toxicity in the combination treatment.
Our future directions include further examining the hepatotoxicity that was indicated by
the metabolic panel with the high ALT and AST enzyme levels. We recently injected F420 tumor
cells in mice to begin a large scale metabolic panel study. In this study, mice will be divided into
the following cohorts: PBS, HSV1716 alone, trabectedin alone, and the combination of
trabectedin and HSV1716. Mice from each cohort will either be euthanized on day 3 or day 7
following the initiation of treatment and blood will be collected for serum analysis. The goal of
this study is to confirm that the toxicity of the combination treatment is caused by damage to the
liver.
The next study we would like to complete is to examine if the toxicity is strain specific.
In our preliminary data, we demonstrated that the toxicity (and efficacy) of the combination
treatment was eliminated in the athymic nude mouse model. However, it is difficult to determine
from this study if the lack of toxicity is T-cell dependent or strain dependent. We will determine
if the toxicity is strain specific for C57BL/6 mice by comparing this mouse model to another
immunocompetent mouse background, balb/c mice. In this study, we will utilize 4T1 cells, a
mammary carcinoma, as F420 cells cannot be grown in balb/c mice. We will complete a survival
study with the four cohorts: PBS, HSV1716, trabectedin, and the combination of trabectedin and
HSV1716. If the toxicity is reduced in the balb/c model, it would confirm that the toxicity of the
combination therapy is C57BL/6 strain dependent.
Finally, future directions for this project include substituting trabectedin for a recently
approved analog, lurbinectedin. Similar to trabectedin, lurbinectedin is a DNA minor-groove
binder that is thought to affect the tumor microenvironment by depleting macrophages19. Early
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studies on lurbinectedin suggest it may be less toxic than trabectedin19. As such, this warrants us
to complete a study in which the combination of trabectedin and HSV1716 is compared to the
combination treatment of lurbinectedin and HSV1716.
Several limitations may have influenced our study results. One important consideration is
that oncolytic viruses have higher replication levels in human cells. As such, a reduction of viral
replication in the murine models could lead to diminishing efficacy. This would explain the
reduced efficacy we have seen in murine models. Ultimately, there still remains a need for the
development of treatments for pediatric solid tumors, especially in case of relapsed or malignant
disease. Oncolytic viruses in combination with other therapeutics, such as trabectedin, need to be
investigated further to determine if they can be developed into viable treatment options.
27
Materials and Methods
Cell Lines and Virus. For the syngeneic studies, we used the F420 osteosarcoma cell line. All
cell lines identities were confirmed by short tandem repeat genotyping, and mycoplasma testing.
We used HSV1716 as the oHSV virus (delivered at 1.0 x 108 pfu).
Compounds and Reagents. Trabectedin is provided by Janssen Pharmaceutical Companies of
Johnson and Johnson.
Animal Studies. All animal studies were approved by the Institutional Animal Care and Use
Committee for the Abigail Wexner Research Institute at Nationwide Children’s Hospital.
C57BL/6 and C57BL/6 albino mice were used in the studies.
In Vivo Efficacy Studies. Tumors were implanted subcutaneously on the flank of the mice. Once
tumors reach a mean volume between 150 mm2 and 250 mm2, the mice were randomized into
four study groups: control (PBS), HSV1716 alone, trabectedin alone, and the combination of
trabectedin and HSV1716. Trabectedin was administered via a tail vein injection, and HSV1716
was delivered intratumorally. Virus was given on day 0, day 2, and day 4. Trabectedin was given
on day 0 and day 7 (Studies that deviated from this general scheme have detailed descriptions of
how the treatment was changed under their appropriate study analysis). The mice were followed
until the animals reached endpoint criteria (tumor volume >2000mm2, unusual mouse behavior,
lack of movement, poor posture, or body weight loss >20%) or 60 days. During the study, tumor
size was measured using calipers twice each week. Tumor volume is calculated by the formula:
(length of tumor) x (width of tumor)2 x (π/6). Mice were humanely euthanized by CO2
asphyxiation and cervical dislocation once endpoint criteria was met.
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